LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and...
Read More Details
Finally We wish PressBee provided you with enough information of ( Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 )
Also on site :
- Planting the seeds for remembering
- Prabowo hails BRICS entry, reaffirms Indonesia’s non-aligned stance
- 'Hissing door mid-air': AI flight to Hong Kong spooks flyers; crew use napkins to 'fix' issue